Tenaya Therapeutics, Inc.

We are a clinical-stage biotechnology company focused on discovering, developing, and delivering therapies for heart disease by addressing its underlying causes. Heart disease is the leading cause of death globally. In the U.S., a cardiovascular-related health condition causes one death every 34 seconds, accounting for one in every three deaths annually. Congenital heart disease (CHD) affects one in 20 adults, and approximately 40,000 children are born with CHD in the U.S. each year, making it the leading cause of birth defect-related illness and death. Despite the need for better treatments, cardiovascular drug approvals have decreased, and few address the root causes of these diseases. Our understanding of the genetic links to heart disease is growing, revealing new opportunities for therapies that target these underlying causes. Roughly one-third to one-half of all heart diseases are linked to genetic risks, and over 250 genetically defined disorders primarily involve the heart. We aim to change heart disease treatment by leveraging this genetic understanding and precision medicine. Our primary focus is on advancing two clinical-stage gene therapy candidates: TN-201, for MYBPC3-associated hypertrophic cardiomyopathy (HCM), and TN-401, for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Both candidates are currently undergoing Phase 1b/2 clinical testing to determine the safety and efficacy of two different doses.